BetterScholar BetterScholar
12
Role
Title
Level Year L/R
🐒 Notice
18 auth. D. Cattran, J. Feehally, H. Cook, Zhihong Liu, F. Fervenza, S. Mezzano, J. Floege, P. Nachman, D. Gipson, M. Praga, ... R. Glassock, J. Radhakrishnan, E. Hodson, B. Rovin, V. Jha, S. Troyanov, P. Li, J. Wetzels
10 2012
10
🐒
🐜 Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.
57 auth. B. Astor, K. Matsushita, R. Gansevoort, Marije van der Velde, M. Woodward, A. Levey, P. D. Jong, J. Coresh, B. Astor, P. D. de Jong, M. El-Nahas, K. Eckardt, B. Kasiske, J. Wright, L. Appel, ... T. Greene, A. Levin, O. Djurdjev, D. Wheeler, M. Landray, J. Townend, J. Emberson, Laura E. Clark, A. Macleod, A. Marks, T. Ali, N. Fluck, G. Prescott, David H. Smith, J. Weinstein, Eric S. Johnson, M. Thorp, J. Wetzels, P. Blankestijn, A. V. van Zuilen, V. Menon, M. Sarnak, G. Beck, F. Kronenberg, B. Kollerits, M. Froissart, B. Stengel, M. Metzger, G. Remuzzi, P. Ruggenenti, A. Perna, H. Heerspink, B. Brenner, D. de Zeeuw, P. Rossing, H. Parving, P. Auguste, Kasper Veldhuis, Yaping Wang, Laura Camarata, B. Thomas, Tom Manley
9 2011
9
🐜
🐜 KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
28 auth. B. Rovin, S. Adler, J. Barratt, F. Bridoux, Kelly A. Burdge, T. Chan, H. Cook, F. Fervenza, K. Gibson, R. Glassock, D. Jayne, V. Jha, A. Liew, Zhi-Hong Liu, J. MejΓ­a-Vilet, ... C. Nester, J. Radhakrishnan, Elizabeth M. Rave, H. Reich, P. Ronco, J. Sanders, S. Sethi, Yusuke Suzuki, S. Tang, V. Tesar, M. Vivarelli, J. Wetzels, J. Floege
9 2021
9
🐜
🐜 Cardiovascular and noncardiovascular mortality among patients starting dialysis.
13 auth. Dinanda J. de Jager, D. Grootendorst, K. Jager, P. V. van Dijk, L. J. Tomas, D. Ansell, F. Collart, P. Finne, J. Heaf, J. D. De Meester, ... J. Wetzels, F. Rosendaal, F. Dekker
9 2009
9
🐜
🐜 Age and association of kidney measures with mortality and end-stage renal disease.
16 auth. S. Hallan, K. Matsushita, Y. Sang, B. Mahmoodi, C. Black, A. Ishani, N. Kleefstra, David M J Naimark, P. Roderick, M. Tonelli, ... J. Wetzels, B. Astor, R. Gansevoort, A. Levin, C. Wen, J. Coresh
9 2012
9
🐜
🐜 Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
35 auth. B. Rovin, S. Adler, J. Barratt, F. Bridoux, Kelly A. Burdge, T. Chan, H. Cook, F. Fervenza, K. Gibson, R. Glassock, D. Jayne, V. Jha, A. Liew, Zhi-Hong Liu, J. MejΓ­a-Vilet, ... C. Nester, J. Radhakrishnan, Elizabeth M. Rave, H. Reich, P. Ronco, J. Sanders, S. Sethi, Yusuke Suzuki, S. Tang, V. Tesar, M. Vivarelli, J. Wetzels, L. Lytvyn, J. Craig, D. Tunnicliffe, M. Howell, M. Tonelli, Michael Cheung, A. Earley, J. Floege
8 2021
8
🐜
🐜 Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.
29 auth. H. Stanescu, M. Arcos-Burgos, A. Medlar, D. Bockenhauer, Anna Kottgen, L. Dragomirescu, C. Voinescu, N. Patel, K. Pearce, M. Hubank, H. Stephens, V. Laundy, S. Padmanabhan, A. Zawadzka, J. Hofstra, ... M. Coenen, M. den Heijer, L. Kiemeney, D. Bacq-Daian, B. Stengel, S. Powis, P. Brenchley, J. Feehally, A. Rees, H. DΔ™biec, J. Wetzels, P. Ronco, P. Mathieson, R. Kleta
8 2011
8
🐜
🐜 Serum hepcidin: reference ranges and biochemical correlates in the general population.
11 auth. T. Galesloot, S. Vermeulen, A. Geurts-Moespot, Siem M. Klaver, Joyce J. C. Kroot, D. van Tienoven, ... J. Wetzels, L. Kiemeney, F. Sweep, M. den Heijer, D. Swinkels
8 2011
8
🐜
🐒 Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
L. Hilbrands, A. Hoitsma, J. Wetzels
8 2005
8
🐒
🐬 Anti-phospholipase Aβ‚‚ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.
J. Hofstra, L. Beck, David M. Beck, J. Wetzels, D. Salant
8 2011
8
🐬
🐒 Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.
9 auth. J. Hofstra, H. DΔ™biec, C. Short, TimotheΓ© PellΓ©, R. Kleta, P. Mathieson, ... P. Ronco, P. Brenchley, J. Wetzels
8 2012
8
🐒
🐜 Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention
8 auth. E. Vegt, M. de Jong, J. Wetzels, R. Masereeuw, M. Melis, W. Oyen, ... M. Gotthardt, O. Boerman
8 2010
8
🐜